SCHEMBL19746574

SCHEMBL19746574

COC(=O)c1c(Cl)sc(Cl)c1C(=O)O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DAO P14920 2/20 0.38
KMT2A Q03164 4/20 0.38
TSHR P16473 3/20 0.38
HSD17B10 Q99714 2/20 0.38
MAPT P10636 2/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
TP53 P04637 2/20 0.37
MDM2 Q00987 1/20 0.37
ALDH1A1 P00352 4/20 0.37
KDM4E B2RXH2 2/20 0.37
LMNA P02545 4/20 0.37
MEN1 O00255 3/20 0.37
HPGD P15428 2/20 0.37
PRKCZ Q05513 1/20 0.37
NGFR P08138 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6058482 0.82 DAO (0.42) DAOTSHRHSD17B10CA12CA1
SCHEMBL162169 0.76 CA12 (0.41) KMT2ATSHRHSD17B10CA12CA1
Dacthal SCHEMBL8539721 0.76 CA12 (0.41) KMT2ATSHRHSD17B10CA12CA1
SCHEMBL25377022 0.74 CA12 (0.48) KMT2ATSHRHSD17B10MAPTCA12
SCHEMBL25380099 0.74 CA12 (0.48) KMT2ATSHRHSD17B10MAPTCA12
SCHEMBL28051326 0.74 CA12 (0.48) KMT2ATSHRHSD17B10MAPTCA12
SCHEMBL25381186 0.74 CA12 (0.48) KMT2ATSHRHSD17B10MAPTCA12
SCHEMBL31149860 0.74 CA12 (0.48) KMT2ATSHRHSD17B10MAPTCA12
SCHEMBL27768938 0.74 CA12 (0.48) KMT2ATSHRHSD17B10MAPTCA12
SCHEMBL11415957 0.74 CA12 (0.48) KMT2ATSHRHSD17B10MAPTCA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163073-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2025-05-22 US disclosed
US-12077547-B2 Aldose reductase inhibitors and methods of use thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2024-09-03 US disclosed
CN-115160339-B Aldose reductase inhibitors and methods of use thereof 纽约市哥伦比亚大学理事会 2024-05-14 CN disclosed
EP-4316603-A2 4-OXO-3,4-DIHYDROTHIENO[3,4-D]PYRIDAZINE COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF The Trustees of Columbia University in the City of New York (US) 2024-02-07 EP disclosed
EP-3757107-B1 4-OXO-3,4-DIHYDROTHIENO[3,4-D]PYRIDAZINE COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF UNIV COLUMBIA (US) 2023-10-25 EP disclosed
EP-3757107-B1 4-OXO-3,4-DIHYDROTHIENO[3,4-D]PYRIDAZINE COMPOUNDS AS ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF UNIV COLUMBIA (US) 2023-10-25 EP disclosed
US-20230312599-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2023-10-05 US disclosed
US-20230312599-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2023-10-05 US disclosed
US-11498925-B2 Aldose reductase inhibitors and methods of use thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2022-11-15 US disclosed
CN-115160339-A Aldose reductase inhibitors and methods of use thereof 纽约市哥伦比亚大学理事会 2022-10-11 CN disclosed
EP-3352754-B1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF UNIV COLUMBIA (US) 2020-09-02 EP disclosed
EP-3352754-B1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF UNIV COLUMBIA (US) 2020-09-02 EP disclosed
US-10647726-B2 Aldose reductase inhibitors and methods of use thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2020-05-12 US disclosed
US-10647726-B2 Aldose reductase inhibitors and methods of use thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2020-05-12 US disclosed
US-20190300543-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2019-10-03 US disclosed
US-20190300543-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2019-10-03 US disclosed
US-10150779-B2 Aldose reductase inhibitors and methods of use thereof THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2018-12-11 US disclosed
US-20180237451-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK 2018-08-23 US disclosed
EP-3352754-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF The Trustees of Columbia University in the City of New York (US) 2018-08-01 EP disclosed
WO-2017223179-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2017-12-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250163073-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF ALDOA, AKR1B1, AKR1C2 DAO 1785/4885KMT2A 4110/4885TSHR 4102/4885
US-11498925-B2 Aldose reductase inhibitors and methods of use thereof ALDOA, AKR1B1, AKR1C2 DAO 1785/4885KMT2A 4110/4885TSHR 4102/4885
US-20180237451-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF ALDOA, AKR1B1, AKR1C2 DAO 1785/4885KMT2A 4110/4885TSHR 4102/4885
US-20190300543-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF ALDOA, AKR1B1, AKR1C2 DAO 1785/4885KMT2A 4110/4885TSHR 4102/4885
US-20230312599-A1 ALDOSE REDUCTASE INHIBITORS AND METHODS OF USE THEREOF ALDOA, AKR1B1, AKR1C2 DAO 1785/4885KMT2A 4110/4885TSHR 4102/4885
US-10150779-B2 Aldose reductase inhibitors and methods of use thereof ALDOA, AKR1B1, AKR1C2 DAO 1785/4885KMT2A 4110/4885TSHR 4102/4885
US-10647726-B2 Aldose reductase inhibitors and methods of use thereof ALDOA, AKR1B1, AKR1C2 DAO 1785/4885KMT2A 4110/4885TSHR 4102/4885
US-12077547-B2 Aldose reductase inhibitors and methods of use thereof ALDOA, AKR1B1, AKR1C2 DAO 1785/4885KMT2A 4110/4885TSHR 4102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.